Abstract:Purpose: To investigate the possibility of using radiofrequency hyperthermia (RFH) to enhance intratumoral therapeutic effect of liposomal doxorubicin on hepatocellular carcinoma (HCC) via an interventional molecular imaging approach. Materials and methods: For both in-vitro confirmation and in-vivo validation, Luciferase/ mCherry-labeled human HCC cells (HepG2) and mice subcutaneous hepatic cancer xenografts were treated by: (i) combination therapy of liposomal doxorubicin plus RFH at 42 degrees C; (ii) liposomal doxorubicin alone; (iii) RFH at 42 degrees C alone; (iv) phosphate buffered saline (PBS) as a control. For in-vitro confirmation, MTS assay, confocal microscopy, optical imaging and flow cytometry were used to evaluate and compare cell viabilities and apoptosis among different treatment groups. For in vivo validation, liposomal doxorubicin was directly injected into the tumor and RFH was performed subsequently under ultrasound imaging guidance. Changes of tumor sizes were quantified using ultrasound imaging and bioluminescence signal intensities after treatments were measured by optical imaging over 14 days, which were correlated with subsequent histology analysis. Results: Of in vitro experiments, MTS assay demonstrated the lowest cell proliferation in combination therapy group compared with the other three groups (25.0 +/- 5.6% vs 49.7 +/- 5.2% vs 94.2 +/- 3.9% vs 100%, respectively, P < 0.001). Flow cytometry showed the highest percentage of early a poptotic HepG2 cells in combination therapy compared to the other three groups (37.9 +/- 3.2% vs 32.2 +/- 1.7% vs 2.9 +/- 1.7% vs 1.8 +/- 0.7%, respectively, P < 0.001). Of in vivo experiments, optical imaging demonstrated a significantly decreased bioluminescence signal intensities in the combination therapy group, compared with the other three groups (0.53 +/- 0.10 VS 1.4 +/- 0.5 VS 2.8 +/- 0.8 VS 3.0 +/- 0.3, P < 0.05). Ultrasound images showed the smallest tumor volumes of the combination therapy group, in comparison to other control groups (0.7 +/- 0.1 VS 1.8 +/- 0.4 VS 3.0 +/- 0.8 VS 3.3 +/- 0.3, P < 0.05). Both histologic correlation confirmed imaging findings. Conclusion: RFH can enhance intratumoral therapy with liposomal doxorubicin for HCC, which is effectively monitored by ultrasound imaging and optical imaging techniques. This concept may provide new avenues for eradicating the residual tumor cells when combining RFA with interventional molecular imaging guided direct intratumoral chemotherapy of HCC.

Recombinant Human Lactoferrin Augments Epirubicin Chemotherapy in Solid Ehrlich Carcinoma Bearing Mice.

Oral recombinant human lactoferrin induces systemic immune responses and inhibits the growth of established tumors

Oral lactoferrin inhibits growth of established tumors and potentiates conventional chemotherapy

[Effect of recombinant super-compound interferon (rSIFN-co) on human breast cancer cells in vitro].

A Novel Human Recombinant Lactoferrin Inhibits Lung Adenocarcinoma Cell Growth and Migration with No Cytotoxic Effect on Normal Human Epithelial Cells

Expression, Purification, and Breast Cancer Cell Inhibiting Effect of Recombinant Human Lactoferrin C-Lobe

Inhibition of breast cancer xenografts in a mouse model and the induction of apoptosis in multiple breast cancer cell lines by lactoferricin B peptide

Recombinant human lactoferrin induces autophagy and apoptosis in human oral cancer Tca8113 cells

The Combination of Two Bioactive Constituents, Lactoferrin and Linolenic Acid, Inhibits Mouse Xenograft Esophageal Tumor Growth by Downregulating Lithocholyltaurine and Inhibiting the JAK2/STAT3-Related Pathway

Intratumoral Radiofrequency Hyperthermia-Enhanced Chemotherapy of Liposomal Doxorubicin on Hepatocellular Carcinoma.

Erythropoietin Intensifies the Proapoptotic Activity of LFM-A13 in Cells and in a Mouse Model of Colorectal Cancer

Recombinant human lactoferrin induces apoptosis, disruption of F-actin structure and cell cycle arrest with selective cytotoxicity on human triple negative breast cancer cells

Enhanced Efficacy of Direct Immunochemotherapy for Hepatic Cancer with Image-Guided Intratumoral Radiofrequency Hyperthermia

Recombinant human lactoferrin carrying humanized glycosylation exhibits antileukemia selective cytotoxicity, microfilament disruption, cell cycle arrest, and apoptosis activities

Engineering of Human Lactoferrin for Improved Anticancer Activity.

Lactobacillus rhamnosus R0011 Treatment Enhanced Efficacy of Capecitabine against Colon Cancer in Male Balb/c Mice

Recombinant human lactoferrin attenuates the progression of hepatosteatosis and hepatocellular death by regulating iron and lipid homeostasis in ob/ob mice.

Anticancer Effect of Bovine Lactoferrin on Human Esophagus Cancer Cell Line

Simultaneous use of erythropoietin and LFM-A13 as a new therapeutic approach for colorectal cancer

Pirfenidone and Vitamin D Ameliorate Cardiac Fibrosis Induced by Doxorubicin in Ehrlich Ascites Carcinoma Bearing Mice: Modulation of Monocyte Chemoattractant Protein-1 and Jun N-terminal Kinase-1 Pathways

Inhibition of human tumor xenograft growth in nude mice by a conjugate of monoclonal antibody LA22 to epidermal growth factor receptor with anti-tumor antibiotics mitomycin C.